NCP, a Dual Kappa and mu Opioid Receptor Agonist, Is a Potent Analgesic Against Inflammatory Pain without Reinforcing or Aversive Properties
Peng Huang,Conrad K Ho,Danni Cao,Saadet Inan,Scott M Rawls,Mengchu Li,Boshi Huang,Piyusha P Pagare,E Andrew Townsend,Justin L Poklis,Matthew S Halquist,Matthew Banks,Yan Zhang,Lee-Yuan Liu-Chen,Conrad K. Ho,Scott M. Rawls,Piyusha P. Pagare,E. Andrew Townsend,Justin L. Poklis,Matthew S. Halquist
DOI: https://doi.org/10.1124/jpet.123.001870
2024-03-16
Journal of Pharmacology and Experimental Therapeutics
Abstract:While agonists of μ (MOR) and (KOR) opioid receptors have analgesic effects, they produce euphoria and dysphoria, respectively. Other side effects include respiratory depression and addiction for MOR agonists and sedation for KOR agonists. We reported that 17-cyclopropylmethyl-3,14 β -dihydroxy-4,5 α -epoxy-6 β -{[4'-(2'-cyanopyridyl)]carboxamido}cmorphinan (NCP) displayed potent KOR full agonist and MOR partial agonist activities (58%) with 6.5x KOR-over-MOR selectivity in vitro. Herein, we characterized pharmacological effects of NCP in rodents. In mice, NCP exerted analgesic effects against inflammatory pain in both the formalin test and the acetic acid writhing test, with A 50 values of 47.6 and 14.4 μ g/kg (s.c.), respectively. The analgesic effects in the acetic acid writhing test were mediated by the KOR. NCP at doses much higher than those effective in reducing inflammatory pain did not produce antinociception in the hot plate and tail flick tests, inhibit compound 48/80-induced scratching, cause conditioned place aversion (CPA) or preference, impair rotarod performance, inhibit locomotor activity, cause respiratory depression, or precipitate morphine withdrawal. However, NCP (10~100 μ g/kg) inhibited gastrointestinal transit with a maximum of ~40% inhibition. In MOR knockout mice, NCP caused CPA, demonstrating that its lack of CPA is due to combined actions on the MOR and KOR. Following subcutanous injection, NCP penetrated into the mouse brain. In rats trained to self-administer heroin, NCP (1~320 μ g/kg/infusion) did not function as a reinforcer. Thus, NCP produces potent analgesic effects via KOR without side effects except constipation. Therefore, dual full KOR/partial MOR agonists with moderate KOR-over-MOR selectivity may be promising as nonaddictive analgesics for inflammatory pain. SIGNIFICANCE STATEMENT Developing nonaddictive analgesics is crucial for reducing opioid overdose deaths, minimizing drug misuse, and promoting safer pain management practices. Herein, the pharmacology of a potential nonaddictive analgesic, NCP, is reported. NCP has full KOR agonist/partial MOR agonist activities with a 6.5x selectivity for KOR over MOR. Unlike MOR agonists, analgesic doses of NCP do not lead to self-administration or respiratory depression. Furthermore, NCP does not produce aversion, hypolocomotion, or motor incoordination, side effects typically associated with KOR activation.
pharmacology & pharmacy